Standard Historical Income Statement
| LAB Stock | USD 1.82 0.11 6.43% |
Historical analysis of Standard Biotools income statement accounts such as Gross Profit of 48.5 M can show how well Standard Biotools performed in making a profits. Evaluating Standard Biotools income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Standard Biotools's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Standard Biotools latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Standard Biotools is a good buy for the upcoming year.
Standard |
About Standard Income Statement Analysis
Standard Biotools Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Standard Biotools shareholders. The income statement also shows Standard investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Standard Biotools Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Standard Biotools generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Standard Biotools minus its cost of goods sold. It is profit before Standard Biotools operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Standard Biotools. It is also known as Standard Biotools overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Standard Biotools' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Standard Biotools current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.At present, Standard Biotools' Research Development is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 2.5 M, whereas Depreciation And Amortization is forecasted to decline to about 10.8 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.8M | 4.3M | 4.6M | 4.5M | Depreciation And Amortization | 23.2M | 15.0M | 15.2M | 10.8M |
Standard Biotools income statement Correlations
Click cells to compare fundamentals
Standard Biotools Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Standard Biotools income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 17.2M | 17.9M | 23.2M | 15.0M | 15.2M | 10.8M | |
| Interest Expense | 4.3M | 3.6M | 3.8M | 4.3M | 4.6M | 4.5M | |
| Total Revenue | 117.2M | 138.1M | 130.6M | 97.9M | 106.3M | 85.3M | |
| Gross Profit | 64.3M | 83.3M | 77.3M | 37.1M | 50.5M | 48.5M | |
| Other Operating Expenses | 169.1M | 189.2M | 198.0M | 214.2M | 169.4M | 133.1M | |
| Operating Income | (51.8M) | (51.0M) | (67.5M) | (116.2M) | (76.6M) | (72.8M) | |
| Ebit | (51.8M) | (52.5M) | (67.5M) | (188.6M) | (69.6M) | (73.1M) | |
| Research Development | 31.6M | 36.5M | 37.9M | 38.5M | 25.9M | 28.8M | |
| Ebitda | (34.6M) | (34.6M) | (44.3M) | (173.6M) | (54.5M) | (57.2M) | |
| Cost Of Revenue | 53.0M | 54.8M | 53.3M | 60.9M | 55.9M | 36.7M | |
| Total Operating Expenses | 116.1M | 134.4M | 144.7M | 153.3M | 113.5M | 96.3M | |
| Income Before Tax | (66.7M) | (54.1M) | (63.7M) | (192.9M) | (74.2M) | (77.9M) | |
| Total Other Income Expense Net | (14.9M) | (3.1M) | 3.8M | (76.7M) | 2.4M | 2.5M | |
| Net Income | (64.8M) | (53.0M) | (59.2M) | (190.1M) | (74.7M) | (78.4M) | |
| Income Tax Expense | (1.9M) | (1.1M) | (4.4M) | (2.8M) | 452K | 474.6K | |
| Tax Provision | (1.9M) | (1.1M) | (4.4M) | (2.8M) | 684K | 718.2K | |
| Interest Income | 4.3M | 3.6M | 3.8M | 64.4M | 74.1M | 77.8M | |
| Selling General Administrative | 84.5M | 97.9M | 98.9M | 114.8M | 98.9M | 102.8M | |
| Net Income Applicable To Common Shares | (64.8M) | (53.0M) | (59.2M) | (190.1M) | (171.1M) | (162.5M) | |
| Net Interest Income | (4.3M) | (3.6M) | (3.8M) | (4.3M) | (4.7M) | (4.9M) | |
| Net Income From Continuing Ops | (64.8M) | (53.0M) | (59.2M) | (190.1M) | (75.7M) | (79.5M) | |
| Reconciled Depreciation | 15.8M | 15.9M | 15.6M | 15.0M | 14.9M | 12.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.558 | Quarterly Revenue Growth (0.14) | Return On Assets (0.15) | Return On Equity (0.37) |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.